Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TLR2 | O60603 | 3/20 | 0.54 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7392221 | 1.00 | MDM2 (0.57) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL29975950 | 1.00 | MDM2 (0.57) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL30441695 | 1.00 | MDM2 (0.57) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL17669898 | 1.00 | MDM2 (0.57) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL29400691 | 1.00 | MDM2 (0.57) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL2267346 | 0.97 | KMT2A (0.58) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL29401707 | 0.97 | KMT2A (0.58) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL12040103 | 0.97 | KMT2A (0.58) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL999302 | 0.97 | KMT2A (0.58) | MDM2KMT2ATLR2TLR1MDM4 | |
| SCHEMBL29362262 | 0.97 | KMT2A (0.58) | MDM2KMT2ATLR2TLR1MDM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12098216-B2 | Modulators of programmed death-ligand-1 and/or programmed death-ligand-2 | SOUTHERN RESEARCH INSTITUTE (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024129600-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024112612-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-11674136-B2 | DNA-templated macrocycle library | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230029187-A1 | MODULATORS OF PROGRAMMED DEATH-LIGAND-1 AND/OR PROGRAMMED DEATH-LIGAND-2 | SOUTHERN RESEARCH INSTITUTE | 2023-01-26 | — | — | US | disclosed |
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | UAB RESEARCH FOUNDATION (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION (US) | 2021-10-21 | — | — | US | disclosed |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | SOUTHERN RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3204403-B1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2020033317-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019168654-A9 | DNA-TEMPLATED MACROCYCLE LIBRARY | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
| US-20190125730-A1 | OXADIAZOLES AND THIADIAZOLES AS TGF-BETA INHIBITORS | UAB RESEARCH FOUNDATION | 2019-05-02 | — | — | US | disclosed |
| EP-3204403-A1 | IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9732119-B2 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-15 | — | — | US | disclosed |
| WO-2016057624-A1 | IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102122-A1 | Immunomodulators | BRISTOL-MYERS SQUIBB COMPANY | 2016-04-14 | — | — | US | disclosed |
| WO-2010132852-A2 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102122-A1 | Immunomodulators | CD274, PDCD1, PDCD1LG2 | MDM2 980/4885KMT2A 2957/4885TLR2 166/4885 |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | MDM2 3999/4885KMT2A 2228/4885TLR2 3825/4885 |
| US-11674136-B2 | DNA-templated macrocycle library | IDE, IAPP, POLRMT | MDM2 938/4885KMT2A 3958/4885TLR2 4684/4885 |
| US-20230029187-A1 | MODULATORS OF PROGRAMMED DEATH-LIGAND-1 AND/OR PROGRAMMED DEATH-LIGAND-2 | PDCD1LG2, CD274, PDCD1 | MDM2 501/4885KMT2A 1671/4885TLR2 204/4885 |
| US-20210323933-A1 | PIPERAZINE-2,5-DIONES AS TGF-BETA INHIBITORS | TGFBR2, SMAD2, TGFB2 | MDM2 1722/4885KMT2A 1099/4885TLR2 394/4885 |
| US-20190127420-A1 | DIPEPTIDE ANALOGS AS TGF-BETA INHIBITORS | TGFB1, TGFB2, SMAD3 | MDM2 993/4885KMT2A 1644/4885TLR2 417/4885 |
| US-11505531-B2 | Piperazine-2,5-diones as TGF-beta inhibitors | TGFBR2, SMAD2, TGFB2 | MDM2 1722/4885KMT2A 1099/4885TLR2 394/4885 |
| US-12098216-B2 | Modulators of programmed death-ligand-1 and/or programmed death-ligand-2 | PDCD1LG2, CD274, PDCD1 | MDM2 501/4885KMT2A 1671/4885TLR2 204/4885 |
| US-20190125730-A1 | OXADIAZOLES AND THIADIAZOLES AS TGF-BETA INHIBITORS | SMAD3, TGFBR1, TGFBR2 | MDM2 1774/4885KMT2A 2643/4885TLR2 1112/4885 |
| US-11046729-B2 | Dipeptide analogs as TGF-beta inhibitors | TGFB1, TGFB2, SMAD3 | MDM2 993/4885KMT2A 1644/4885TLR2 417/4885 |
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | MDM2 4095/4885KMT2A 3160/4885TLR2 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.